Core Viewpoint - Nanjing University has announced procurement intentions for 16 items of scientific instruments and equipment, with a total budget of 90.15 million yuan, scheduled for purchase between May and September 2025 [1][2]. Procurement Overview - The procurement includes advanced scientific instruments such as: - Three-channel wavelength-tunable femtosecond laser [3] - Rotating high magnetic field dilution refrigerator [3] - Atomic layer etching (ALE) equipment [3] - Semiconductor electronic measurement system [3] - Superconducting quantum interference magnetic measurement system [3] - The total budget for these items is 90.15 million yuan, with individual budgets for specific equipment ranging from 150,000 to 3 million yuan [2][3]. Specific Equipment Details - **Three-channel wavelength-tunable femtosecond laser**: - Budget: 202 million yuan - Applications: Condensed matter ultrafast dynamics, molecular dynamics, ultrafast optics, attosecond optics [3]. - **Rotating high magnetic field dilution refrigerator**: - Budget: 500 million yuan - Requirements: Continuous stable operation at temperatures as low as 12 mK and a magnetic field strength of no less than 14 Tesla [3]. - **Atomic layer etching (ALE) equipment**: - Budget: 860 million yuan - Features: Stainless steel/aluminum chamber, dual vacuum structure, and customizable reaction gas pathways [3]. - **Semiconductor electronic measurement system**: - Budget: 400 million yuan - Specifications: Compatible with 2-inch wafer measurements, voltage range of ±100V, and current range of ±100mA [3]. - **Superconducting quantum interference magnetic measurement system**: - Budget: 525 million yuan - Usage: High sensitivity magnetic property measurements in extreme low-temperature environments [3]. Additional Equipment - **Wafer transfer system**: - Budget: 200 million yuan - Requirements: Ultra-high vacuum transfer chamber and automated transfer system [3]. - **8-inch two-dimensional semiconductor MOCVD epitaxy system**: - Budget: 1.6 billion yuan - Capabilities: High-temperature growth and automatic sample handling [3]. - **Dynamic nuclear polarization 400 MHz NMR spectrometer**: - Budget: 3 million yuan - Features: Microwave hyperpolarization enhancement for solid-state NMR experiments [6]. - **Laser confocal microscope**: - Budget: 195 million yuan - Purpose: High-resolution three-dimensional imaging and fluorescence spectral analysis [6]. Summary of Procurement Timeline - The procurement is scheduled to take place from May to September 2025, with specific items being acquired in different months [4][6].

导读： 6项新国标将实施，公共场所卫生标准升级，新增9类健康指标检测，涵盖空气流通、有害物质、病菌防控等，提升公共场所卫 生安全。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近 日 ， 市 场 监 管 总 局 （ 国 家 标 准 委 ） 批 准 发 布 《 公 共 场 所 卫 生 检 验 方 法 第 1 部 分 ： 物 理 性 指 标 》 （ GB/T18204.1— 2025）等6项国家标准。该系列标准由国家疾控局组织修订，将于2025年12月1日起正式实施。 近年来，公共场所卫生安全受到社会广泛关注，为贯彻落实《健康中国行动（2019—2030年）》提出的"建设健康环 境"有关要求，本次标准修订重点解决大家关心的商场、泳池、酒店等场所卫生安全问题，主要有三大变化： 一是检测项目更全面，新增9类健康指标检测，包括新风量和自然采光系数等空气流通方面指标，甲醛、PM2.5、放射 性气体氡等有害物质限量指标，泳池水消毒效果、军团菌（可能引发严重肺炎的细菌）、β-溶血性链球菌（常见致病 菌）等病菌防控相关指标。 二是检测技术更先进，升级了用 ...

Core Viewpoint - XtalPi Holdings Limited has completed the acquisition of Liverpool ChiroChem, enhancing its capabilities in AI-driven autonomous experimental platforms for chemical exploration, which will better serve clients in drug development, new materials discovery, and high-value chemicals [2][4]. Group 1: Acquisition Details - The acquisition of Liverpool ChiroChem (LCC) will strengthen XtalPi's "AI + Robotics" platform in the chemical exploration domain [2]. - LCC's founder, Dr. Paul Colbon, expressed excitement about leveraging AI and robotics to explore a broader chemical space and expedite the discovery of high-value molecules [4]. - LCC, established in 2014, focuses on the design and synthesis of novel chiral molecules and has developed the PACE technology platform, which integrates AI software with automation for efficient molecular screening and synthesis [4][5]. Group 2: Technological Synergy - LCC possesses a leading global database of chiral chemical entities, providing high-quality data support for AI models in chiral molecular exploration [5]. - The collaboration between XtalPi and LCC will enhance capabilities in high-throughput and micro-scale molecular library construction, complementing XtalPi's large-scale molecular library technology [5]. - XtalPi continues to enhance its technical strength in chemical exploration through strategic partnerships, incubation, joint research, and acquisitions [5]. Group 3: Company Background - XtalPi was founded in 2015 by three physicists from MIT and operates as an innovative R&D platform powered by quantum physics, AI, and robotics [6]. - The company provides drug and materials science R&D solutions for global and domestic companies across various industries, including pharmaceuticals, agricultural technology, energy, and new chemicals [6].

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，山西省大气探测技术保障中心发布4项仪器设备采购意向，预算总额达1.89亿元，涉及无人机试验平台、双波长 四通道拉曼激光雷达、冰核采样与分析设备、二维成像降水粒子谱仪、微雨雷达、全天空成像仪、冰雹自动测量设备、 雹雨分测仪、GPS火箭气象探空系统、冰雹微物理结构分析实验室等，预计采购时间为2025年6~10月。 山西省大气探测技术保障中心 2025年6~10月 仪器设备采购 意向汇总表 | | | | 采 | | --- | --- | --- | --- | | | | 预算 | 购 | | 采购项目 | 需求概况 | 万元 | 时 | | | | | 间 | | | | | 202 | | | | | 5 | | 华北区域人工影响天气能力建设项目 | 国家作业飞机及机载大气探测子系统、机载催化作业子系统、空地通信子系统及空地综合业务系统联调 | 15634 | 年 | | （山西）-综合作业能力建设采购项目 | 测试。 | | 6 | | | | | 月 | | | | | 202 | ...

导读： 近日，清华大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出22项仪器设备采购意向，预算 总额达1.48亿元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，清华大学发2 2项仪器设备采购意向，预算总额达1 . 4 8亿元，涉及光谱仪总装、激光闪光光解光谱仪、台式X射线 吸收精细结构谱仪、共聚焦污染物毒性分析仪、多功能酶标仪、荧光定量核酸扩增仪等，预计采购时间为2 0 2 5年6~9 月。 | | | | 采 | | --- | --- | --- | --- | | 采购 | 需求概况 | 预算 | 购 | | 项目 | | 万元 | 时 | | | | | 间 | | | | | 202 | | 光谱仪总 | | | 5 | | 装 | 光谱仪总装 | 10000 | 年 | | | | | 6 月 | | | | | 202 | | 智能驾驶 | | | 5 | | 仿真系统 | 智能驾驶仿真系统 | 125 | 年 | | | | | 9 | | | | | 月 | | | | | 202 | ...

Core Insights - The global scientific instrument industry reported a total net profit of 19.8 billion yuan from 21 listed companies in 2024, showing a slight decline year-on-year, with the average net profit margin dropping to 11.6% from 15.7% in 2023, indicating a slowdown in industry growth and increasing strategic differentiation among companies [1][2]. Group 1: Financial Performance - The top three companies maintained their positions, with Thermo Fisher leading with a net profit of 6.33 billion USD, a profit margin of 14.8%, driven by a decrease in sales costs and an increase in gross profit margin [5]. - Danaher and Merck, while retaining their second and third positions, faced challenges with Danaher's net profit declining for two consecutive years due to a drop in the biotechnology segment, while Merck managed a slight profit decrease of 1.7% through market expansion in emerging regions [5][6]. - Among the 21 companies, 10 had net profit margins significantly above the industry average of 11.6%, highlighting the profitability efficiency of leading firms [8]. Group 2: Strategic Adjustments - Companies like SIBAT and Sartorius showed remarkable performance, with SIBAT achieving a 60.79% increase in net profit despite a 10% revenue decline, demonstrating effective cost control strategies [6]. - Sartorius experienced a 46.1% increase in net profit, attributed to a 16% revenue growth in the North American market and strategic focus on energy measurement [6]. - Agilent, despite a slight revenue decline, successfully implemented cost reduction strategies, resulting in a record high net profit and an improved global ranking [6]. Group 3: Challenges and Market Dynamics - Nine companies, including Zeiss and Veralto, faced profit declines despite revenue growth due to factors like currency fluctuations and rising costs [9]. - Companies such as Illumina and Bio-Rad encountered dual declines in revenue and profit, with Illumina suffering from goodwill impairment and Bio-Rad facing increased restructuring costs [9]. - The industry is experiencing structural adjustments, with emerging markets like Latin America and the Middle East driving growth for some companies, while the Chinese market presents challenges [10]. Group 4: Future Outlook - The ability of Thermo Fisher to return to peak profitability, the effectiveness of Danaher's cost-saving initiatives, and Sartorius's growth potential in energy measurement will be key indicators for the industry's direction [10]. - Companies must address the challenge of achieving sustainable growth through technological innovation, market rebalancing, and operational efficiency amidst overall profit margin pressures [10].

Core Viewpoint - The article highlights the procurement intentions of Central South University’s innovation platform, with a total budget of 191.579 million yuan for various advanced scientific instruments, expected to be purchased between July and December 2025 [1][2]. Procurement Overview - The procurement includes a range of sophisticated instruments such as: - Ultraviolet-visible near-infrared quantum efficiency tester (112.86 million yuan) [3] - Three-dimensional reconstruction focused ion beam electron microscope (1.3 billion yuan) [4] - High-sensitivity photoelectric and electro-optical conversion quantum efficiency tester (980 million yuan) [4] - Energy loss tester (283 million yuan) [4] - Various testing machines for mechanical properties, including high-temperature creep relaxation testing machines and electronic fatigue testing machines [3][4]. Budget Allocation - The total budget of 191.579 million yuan is allocated across multiple projects, with significant amounts dedicated to: - High-temperature and low-temperature testing equipment [3][4] - Advanced imaging systems such as X-ray fluorescence spectrometers and electron microscopes [4][5]. Expected Procurement Timeline - The expected procurement period is set for July to December 2025, indicating a strategic planning phase for the university's research capabilities [2][3]. Instrument Specifications - Specific instruments listed for procurement include: - Multi-field coupled low-field nuclear magnetic imaging system (450 million yuan) [4] - Soft X-ray electron probe analysis system (800 million yuan) [5] - Glow discharge mass spectrometer (970 million yuan) [5]. Conclusion - The procurement initiative reflects Central South University's commitment to enhancing its research infrastructure through significant investments in advanced scientific instruments, which may present opportunities for suppliers and manufacturers in the scientific equipment sector [1][2].

Core Viewpoint - The article emphasizes the growing importance of mass spectrometry technology in clinical diagnostics, driven by the need for earlier detection, more precise diagnosis, and comprehensive evaluation in the context of precision medicine and individualized treatment [1]. Group 1: Industry Trends - The trend in clinical diagnostics is moving towards "earlier detection, more precise diagnosis, and comprehensive evaluation," which aligns with the advancements in precision medicine [1]. - Mass spectrometry is recognized for its high sensitivity, specificity, and capability for simultaneous detection of multiple components, making it a key technology in the transformation of clinical testing [1]. Group 2: Clinical Applications - Mass spectrometry has been widely applied for the precise detection of small molecules and is gradually expanding into the detection of larger biomolecules such as proteins, peptides, and nucleic acids [1]. - The technology supports early disease screening, subtype diagnosis, and efficacy evaluation, providing reliable technical support for clinical applications [1]. Group 3: Upcoming Event - A network seminar titled "Fourth Clinical Mass Spectrometry Technology and Application Progress" is scheduled for June 12, 2025, organized by Instrument Information Network, to discuss the future development paths of clinical mass spectrometry [2][3].

导读： 本文深度聚焦国内50家上市仪器公司，通过解析2024年度研发投入金额、占比、人员规模等关键数据，绘制出一份全景式创新图谱。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 科学仪器，被誉为现代工业的"隐形基石"和科技创新的"眼睛与双手"。从基础研究到产业升级，从实验室探索到高端制造，仪器的精度与可靠 性直接决定着科研的高度与产业的质量。然而，这一关键领域曾长期被国际巨头垄断，国产仪器的"卡脖子"之痛，不仅关乎企业生存，更牵系 国家科技自主的战略安全。 近年来，政策东风频吹——从"十四五"规划的顶层设计，到财政专项的精准滴灌；从进口替代的硬性指标，到产学研协同的技术攻坚，国产科 学仪器行业正迎来前所未有的历史性机遇。在这场必须打赢的"逆袭战"中，研发投入成为企业竞争力的核心标尺：唯有真金白银砸向创新，才 能突破技术壁垒；唯有顶尖人才汇聚，方能锻造出与进口品牌抗衡的"中国精度"。 基于此，仪器信息网深度聚焦国内50家上市仪器企业，通过解析2024年度研发投入金额、占比、人员规模等关键数据，绘制出一份全景式创 新图谱。我们试图回答：谁在引 ...

Core Viewpoint - The issuance of the first prescription for mesenchymal stem cell drugs marks a significant breakthrough in the clinical application of stem cell therapies in China, transitioning from research achievements to accessible treatments [1]. Group 1: Clinical Application of Stem Cell Therapy - On June 5, 2025, the first prescription for a marketed mesenchymal stem cell drug was issued by a team led by Academician Huang Xiaojun at Peking University People's Hospital for a patient undergoing haploidentical transplantation [1]. - The first stem cell therapy drug, Aimi Maito Sai injection (Ruibo Sheng), received conditional approval from NMPA on January 2, 2025, targeting acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation [1]. - This innovative therapy utilizes human umbilical mesenchymal stem cells to regulate T-cell overactivation and inflammatory cytokine storms, providing a new solution for life-threatening immune attacks affecting multiple organs [1]. Group 2: Development of Health Industry in Jiangxi - Jiangxi's Ganjiang New Area is focusing on the life and health industry, aiming to enhance the industrial chain by integrating research and application, forming a cluster that includes traditional Chinese medicine, medical devices, beauty health products, and biomedicine [1]. - Antu Bio, a leading company in the in vitro diagnostics field, is collaborating with the Ganjiang New Area to leverage its strong research capabilities and advanced core technologies to maintain its leading position in the industry [1]. - The partnership aims to promote the deep integration of innovation chains, industrial chains, financial chains, and talent chains, establishing a modern industrial system with distinctive advantages [1]. Group 3: Strategic Positioning of Ganjiang New Area - Ganjiang New Area is recognized as a national-level new area, serving as a comprehensive functional platform with unique policy integration advantages and a conducive industrial development environment [2]. - The area is positioned to become a "bridgehead" and frontier for the high-end development of the in vitro diagnostics industry in Jiangxi Province [2]. - The collaboration with Antu Bio is expected to initiate high-standard and efficient development in artificial intelligence and smart testing systems [3].